

# Barbara Stauch Slusher

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2305507/publications.pdf>

Version: 2024-02-01

210  
papers

12,579  
citations

31976

53  
h-index

32842

100  
g-index

217  
all docs

217  
docs citations

217  
times ranked

14873  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Dendrimer-2PMPA selectively blocks upregulated microglial GCPII activity and improves cognition in a mouse model of multiple sclerosis. <i>Nanotheranostics</i> , 2022, 6, 126-142.                          | 5.2  | 18        |
| 2  | Dendrimer-2PMPA Delays Muscle Function Loss and Denervation in a Murine Model of Amyotrophic Lateral Sclerosis. <i>Neurotherapeutics</i> , 2022, 19, 274-288.  | 4.4  | 9         |
| 3  | Clinical development of metabolic inhibitors for oncology. <i>Journal of Clinical Investigation</i> , 2022, 132, .   | 8.2  | 59        |
| 4  | Thieno[2,3- <i>d</i> ]pyrimidine-Based Positive Allosteric Modulators of Human Mas-Related G Protein-Coupled Receptor X1 (MRGPRX1). <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3218-3228.             | 6.4  | 8         |
| 5  | High-Throughput Activity Assay for Screening Inhibitors of the SARS-CoV-2 Mac1 Macrodomein. <i>ACS Chemical Biology</i> , 2022, 17, 17-23.   | 3.4  | 28        |
| 6  | Comprehensive Metabolic Profiling of MYC-Amplified Medulloblastoma Tumors Reveals Key Dependencies on Amino Acid, Tricarboxylic Acid and Hexosamine Pathways. <i>Cancers</i> , 2022, 14, 1311.               | 3.7  | 10        |
| 7  | Neutral sphingomyelinase 2 inhibition attenuates extracellular vesicle release and improves neurobehavioral deficits in murine HIV. <i>Neurobiology of Disease</i> , 2022, 169, 105734.                      | 4.4  | 11        |
| 8  | Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumors. <i>Cell Death and Disease</i> , 2022, 13, 410. | 6.3  | 4         |
| 9  | A Novel Oral Glutamate Carboxypeptidase II Inhibitor for the Treatment of Inflammatory Bowel Disease. <i>FASEB Journal</i> , 2022, 36, .   | 0.5  | 0         |
| 10 | The pathogenesis of, and pharmacological treatment for, Canavan disease. <i>Drug Discovery Today</i> , 2022, 27, 2467-2483.  | 6.4  | 10        |
| 11 | Inhibition of glutamate-carboxypeptidase-II in dorsolateral prefrontal cortex: potential therapeutic target for neuroinflammatory cognitive disorders. <i>Molecular Psychiatry</i> , 2022, 27, 4252-4263.    | 7.9  | 13        |
| 12 | Glutamine antagonist JHU083 improves psychosocial behavior and sleep deficits in EcoHIV-infected mice. <i>Brain, Behavior, &amp; Immunity - Health</i> , 2022, 23, 100478.                                   | 2.5  | 1         |
| 13 | An efficient synthetic route to l- <sup>13</sup> C-methyleneglutamine and its amide derivatives, and their selective anticancer activity. <i>RSC Advances</i> , 2021, 11, 7115-7128.                         | 3.6  | 1         |
| 14 | Small Molecule Inhibitors Targeting Biosynthesis of Ceramide, the Central Hub of the Sphingolipid Network. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 279-297.  | 6.4  | 26        |
| 15 | FSMP-18. COMPREHENSIVE METABOLIC PROFILING OF HIGH MYC MEDULLOBLASTOMA REVEALS KEY DIFFERENCES BETWEEN IN VITRO AND IN VIVO GLUCOSE AND GLUTAMINE USAGE. <i>Neuro-Oncology Advances</i> , 2021, 3, i19-i19.  | 0.7  | 0         |
| 16 | Novel Glutamine Antagonist JHU395 Suppresses MYC-Driven Medulloblastoma Growth and Induces Apoptosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 336-344.                       | 1.7  | 16        |
| 17 | Characterization of extracellular vesicles and synthetic nanoparticles with four orthogonal single-particle analysis platforms. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12079.                 | 12.2 | 97        |
| 18 | TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma. <i>Cancer Letters</i> , 2021, 504, 137-145.                             | 7.2  | 5         |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Abstract 2321: Comprehensive metabolic profiling of high MYC medulloblastoma revealed key differences between in vitro and in vivo in glucose and glutamine usage. , 2021, , .  |      | 0         |
| 20 | OTME-9. Comprehensive Metabolic Profiling Of high MYC Medulloblastoma Reveals Key Differences Between In Vitro And In Vivo Glucose And Glutamine Usage. <i>Neuro-Oncology Advances</i> , 2021, 3, ii15-ii15.  | 0.7  | 1         |
| 21 | Regulatory T cells reduce endothelial neutral sphingomyelinase 2 to prevent T cell migration into tumors. <i>European Journal of Immunology</i> , 2021, 51, 2317-2329.  | 2.9  | 3         |
| 22 | Nipping disease in the bud: nSMase2 inhibitors as therapeutics in extracellular vesicle-mediated diseases. <i>Drug Discovery Today</i> , 2021, 26, 1656-1668.   | 6.4  | 21        |
| 23 | Glutamine Antagonist GA-607 Causes a Dramatic Accumulation of FGAR which can be used to Monitor Target Engagement. <i>Current Drug Metabolism</i> , 2021, 22, 735-745.  | 1.2  | 4         |
| 24 | High Throughput Screening Cascade To Identify Human Aspartate N-Acetyltransferase (ANAT) Inhibitors for Canavan Disease. <i>ACS Chemical Neuroscience</i> , 2021, 12, 3445-3455.  | 3.5  | 5         |
| 25 | Model studies towards prodrugs of the glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON) containing a diazo precursor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 50, 128321.   | 2.2  | 2         |
| 26 | The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa149.  | 0.7  | 21        |
| 27 | Inhibition of neutral sphingomyelinase 2 reduces extracellular vesicle release from neurons, oligodendrocytes, and activated microglial cells following acute brain injury. <i>Biochemical Pharmacology</i> , 2021, 194, 114796.  | 4.4  | 17        |
| 28 | Glutamate Carboxypeptidase II in Aging Rat Prefrontal Cortex Impairs Working Memory Performance. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 760270.   | 3.4  | 12        |
| 29 | DCC-related developmental effects of abused versus therapeutic like amphetamine doses in adolescence. <i>Addiction Biology</i> , 2020, 25, e12791.  | 2.6  | 20        |
| 30 | The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 397-408.  | 4.1  | 18        |
| 31 | Structure-Activity Relationships for a Series of (Bis(4-fluorophenyl)methyl)sulfinyl Alkyl Alicyclic Amines at the Dopamine Transporter: Functionalizing the Terminal Nitrogen Affects Affinity, Selectivity, and Metabolic Stability. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 2343-2357. | 6.4  | 20        |
| 32 | Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain. <i>Neurochemical Research</i> , 2020, 45, 1256-1267.  | 3.3  | 15        |
| 33 | Inhibition of neutral sphingomyelinase 2 promotes remyelination. <i>Science Advances</i> , 2020, 6, .   | 10.3 | 23        |
| 34 | Sowing the Seeds of Discovery: Tau-Propagation Models of Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3499-3509.   | 3.5  | 7         |
| 35 | Glutamine Antagonist JHU-083 Normalizes Aberrant Hippocampal Glutaminase Activity and Improves Cognition in APOE4 Mice. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 437-447.  | 2.6  | 15        |
| 36 | Allosteric kidney-type glutaminase (GLS) inhibitors with a mercaptoethyl linker. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115698.  | 3.0  | 6         |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 37 | Targeting Mitochondria in Tumor-Associated Macrophages using a Dendrimer-Conjugated TSPO Ligand that Stimulates Antitumor Signaling in Glioblastoma. <i>Biomacromolecules</i> , 2020, 21, 3909-3922.  | 5.4  | 23        |
| 38 | Bioenergetic adaptations to HIV infection. Could modulation of energy substrate utilization improve brain health in people living with HIV-1?. <i>Experimental Neurology</i> , 2020, 327, 113181.   | 4.1  | 6         |
| 39 | Novel Human Neutral Sphingomyelinase 2 Inhibitors as Potential Therapeutics for Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 6028-6056.   | 6.4  | 26        |
| 40 | Astrocytes deliver CK1 to neurons via extracellular vesicles in response to inflammation promoting the translation and amyloidogenic processing of APP. <i>Journal of Extracellular Vesicles</i> , 2020, 10, e12035.  | 12.2 | 29        |
| 41 | Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. <i>Journal of Clinical Investigation</i> , 2020, 130, 3865-3884.   | 8.2  | 230       |
| 42 | JHU-083 selectively blocks glutaminase activity in brain CD11b+ cells and prevents depression-associated behaviors induced by chronic social defeat stress. <i>Neuropsychopharmacology</i> , 2019, 44, 683-694.   | 5.4  | 38        |
| 43 | A novel and potent brain penetrant inhibitor of extracellular vesicle release. <i>British Journal of Pharmacology</i> , 2019, 176, 3857-3870.   | 5.4  | 33        |
| 44 | Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma. <i>Translational Oncology</i> , 2019, 12, 1314-1322.   | 3.7  | 46        |
| 45 | Glutamine Antagonist JHU083 Normalizes Aberrant Glutamate Production and Cognitive Deficits in the EcoHIV Murine Model of HIV-Associated Neurocognitive Disorders. <i>Journal of Neuroimmune Pharmacology</i> , 2019, 14, 391-400.  | 4.1  | 29        |
| 46 | Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. <i>Science</i> , 2019, 366, 1013-1021.  | 12.6 | 643       |
| 47 | Spontaneous Loss-of-Function Dock2 Mutation Alters Murine Colitis Sensitivity and Is a Confounding Variable in Inflammatory Bowel Disease Research. <i>Crohn's &amp; Colitis</i> 360, 2019, 1, .  | 1.1  | 2         |
| 48 | Glutamine antagonism attenuates physical and cognitive deficits in a model of MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2019, 6, .  | 6.0  | 12        |
| 49 | Discovery of Benzamidine- and 1-Aminoisoquinoline-Based Human MAS-Related G-Protein-Coupled Receptor X1 (MRCPRX1) Agonists. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8631-8641.  | 6.4  | 19        |
| 50 | Enhanced Oral Bioavailability of 2-(Phosphonomethyl)-pentanedioic Acid (2-PMPA) from its (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl (ODOL)-Based Prodrugs. <i>Molecular Pharmaceutics</i> , 2019, 16, 4292-4301.  | 4.6  | 13        |
| 51 | Investigation of Novel Primary and Secondary Pharmacophores and 3-Substitution in the Linking Chain of a Series of Highly Selective and Bitopic Dopamine D <sub>3</sub> Receptor Antagonists and Partial Agonists. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 9061-9077. | 6.4  | 30        |
| 52 | Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine. <i>Clinical Cancer Research</i> , 2019, 25, 5925-5936.  | 7.0  | 22        |
| 53 | The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D <sub>3</sub> Receptor (D <sub>3</sub> R) Selective Agonists. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 6287-6314.  | 6.4  | 26        |
| 54 | Upregulation of the Glutaminase II Pathway Contributes to Glutamate Production upon Glutaminase I Inhibition in Pancreatic Cancer. <i>Proteomics</i> , 2019, 19, e1800451.  | 2.2  | 36        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Tumor-Targeted Delivery of 6-Diazo-5-oxo-L-norleucine (DON) Using Substituted Acetylated Lysine Prodrugs. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 3524-3538.   | 6.4 | 36        |
| 56 | The NAAG™ Concerns of Modeling Human Alzheimer™s Disease in Mice. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 939-945.   | 2.6 | 5         |
| 57 | Neutral sphingomyelinase 2 inhibitors based on the 4-(1H-imidazol-2-yl)-2,6-dialkoxyphenol scaffold. <i>European Journal of Medicinal Chemistry</i> , 2019, 170, 276-289.  | 5.5 | 11        |
| 58 | Intranasal insulin therapy reverses hippocampal dendritic injury and cognitive impairment in a model of HIV-associated neurocognitive disorders in EcoHIV-infected mice. <i>Aids</i> , 2019, 33, 973-984.            | 2.2 | 37        |
| 59 | Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin. <i>Neuro-Oncology</i> , 2019, 21, 252-263.  | 1.2 | 21        |
| 60 | Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects. <i>Neuropsychopharmacology</i> , 2019, 44, 1415-1424.                   | 5.4 | 61        |
| 61 | Structural and computational basis for potent inhibition of glutamate carboxypeptidase II by carbamate-based inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 255-264.                              | 3.0 | 21        |
| 62 | N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 3918-3929.                                    | 6.4 | 33        |
| 63 | Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1343-1353.  | 0.7 | 21        |
| 64 | Pharmacokinetics of Intranasal versus Subcutaneous Insulin in the Mouse. <i>ACS Chemical Neuroscience</i> , 2018, 9, 809-816.  | 3.5 | 28        |
| 65 | The Low-Affinity Binding of Second Generation Radiotracers Targeting TSPO is Associated with a Unique Allosteric Binding Site. <i>Journal of NeuroImmune Pharmacology</i> , 2018, 13, 1-5.                           | 4.1 | 14        |
| 66 | Atypical dopamine transporter inhibitors attenuate compulsive-like methamphetamine self-administration in rats. <i>Neuropharmacology</i> , 2018, 131, 96-103.  | 4.1 | 21        |
| 67 | Peripheral Neuropathy Induced by Microtubule-Targeted Chemotherapies: Insights into Acute Injury and Long-term Recovery. <i>Cancer Research</i> , 2018, 78, 817-829.   | 0.9 | 54        |
| 68 | DPTIP, a newly identified potent brain penetrant neutral sphingomyelinase 2 inhibitor, regulates astrocyte-peripheral immune communication following brain inflammation. <i>Scientific Reports</i> , 2018, 8, 17715. | 3.3 | 41        |
| 69 | MRI demonstrates glutamine antagonist-mediated reversal of cerebral malaria pathology in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E12024-E12033.    | 7.1 | 26        |
| 70 | Ghrelin agonist HM01 attenuates chemotherapy-induced neurotoxicity in rodent models. <i>European Journal of Pharmacology</i> , 2018, 840, 89-103.  | 3.5 | 15        |
| 71 | Structural basis for potent inhibition of d-amino acid oxidase by thiophene carboxylic acids. <i>European Journal of Medicinal Chemistry</i> , 2018, 159, 23-34.   | 5.5 | 6         |
| 72 | We're Not â€œDONâ€ Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1824-1832.   | 4.1 | 148       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | NaV1.1 inhibition can reduce visceral hypersensitivity. JCI Insight, 2018, 3, .   | 5.0 | 34        |
| 74 | Local enema treatment to inhibit FOLH1 /GCP II as a novel therapy for inflammatory bowel disease. Journal of Controlled Release, 2017, 263, 132-138.  | 9.9 | 20        |
| 75 | Development of a primary microglia screening assay and its use to characterize inhibition of system xc- by erastin and its analogs. Biochemistry and Biophysics Reports, 2017, 9, 266-272.  | 1.3 | 11        |
| 76 | Role of Academic Drug Discovery in the Quest for New CNS Therapeutics. ACS Chemical Neuroscience, 2017, 8, 429-431.   | 3.5 | 19        |
| 77 | Microtubule-Targeting Agents Eribulin and Paclitaxel Differentially Affect Neuronal Cell Bodies in Chemotherapy-Induced Peripheral Neuropathy. Neurotoxicity Research, 2017, 32, 151-162.   | 2.7 | 20        |
| 78 | Glutamine antagonist-mediated immune suppression decreases pathology but delays virus clearance in mice during nonfatal alphavirus encephalomyelitis. Virology, 2017, 508, 134-149.   | 2.4 | 18        |
| 79 | The Psychiatric Impact of HIV. ACS Chemical Neuroscience, 2017, 8, 1432-1434.   | 3.5 | 34        |
| 80 | Valley of death: A proposal to build a "translational bridge" for the next generation. Neuroscience Research, 2017, 115, 1-4.   | 1.9 | 33        |
| 81 | Discovery of a <i>para</i> -Acetoxy-benzyl Ester Prodrug of a Hydroxamate-Based Glutamate Carboxypeptidase II Inhibitor as Oral Therapy for Neuropathic Pain. Journal of Medicinal Chemistry, 2017, 60, 7799-7809.  | 6.4 | 21        |
| 82 | <i>N</i> -(Pivaloyloxy)alkoxy-carbonyl Prodrugs of the Glutamine Antagonist 6-Diazo-5-oxo-norleucine (DON) as a Potential Treatment for HIV Associated Neurocognitive Disorders. Journal of Medicinal Chemistry, 2017, 60, 7186-7198.   | 6.4 | 56        |
| 83 | Enhanced Brain Delivery of 2-(Phosphonomethyl)pentanedioic Acid Following Intranasal Administration of Its $\beta$ -Substituted Ester Prodrugs. Molecular Pharmaceutics, 2017, 14, 3248-3257.   | 4.6 | 8         |
| 84 | Structure-Activity Relationship Studies on a Series of $3\beta$ -[Bis(4-fluorophenyl)methoxy]tropanes and $3\beta$ -[Bis(4-fluorophenyl)methylamino]tropanes As Novel Atypical Dopamine Transporter (DAT) Inhibitors for the Treatment of Cocaine Use Disorders. Journal of Medicinal Chemistry, 2017, 60, 10172-10187. | 6.4 | 15        |
| 85 | Prostate-specific membrane antigen (PSMA)-mediated laminin proteolysis generates a pro-angiogenic peptide. Angiogenesis, 2016, 19, 487-500.   | 7.2 | 51        |
| 86 | Paclitaxel causes degeneration of both central and peripheral axon branches of dorsal root ganglia in mice. BMC Neuroscience, 2016, 17, 47.   | 1.9 | 23        |
| 87 | Unprecedented Binding Mode of Hydroxamate-Based Inhibitors of Glutamate Carboxypeptidase II: Structural Characterization and Biological Activity. Journal of Medicinal Chemistry, 2016, 59, 4539-4550.  | 6.4 | 18        |
| 88 | Still NAAG™ing After All These Years. Advances in Pharmacology, 2016, 76, 215-255.  | 2.0 | 43        |
| 89 | Highly Selective Dopamine D <sub>3</sub> Receptor (D <sub>3</sub> R) Antagonists and Partial Agonists Based on Eticlopride and the D <sub>3</sub> R Crystal Structure: New Leads for Opioid Dependence Treatment. Journal of Medicinal Chemistry, 2016, 59, 7634-7650.  | 6.4 | 73        |
| 90 | Structural Basis for Induction of Peripheral Neuropathy by Microtubule-Targeting Cancer Drugs. Cancer Research, 2016, 76, 5115-5123.  | 0.9 | 36        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Property-Guided Synthesis of Aza-Tricyclic Indolines: Development of Gold Catalysis En Route. <i>Advanced Synthesis and Catalysis</i> , 2016, 358, 1482-1490.   | 4.3 | 17        |
| 92  | Discovery of 6-Diazo-5-oxo-norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 8621-8633.                                    | 6.4 | 98        |
| 93  | Protective Effects of Glutamine Antagonist 6-Diazo-5-Oxo- -Norleucine in Mice with Alphavirus Encephalomyelitis. <i>Journal of Virology</i> , 2016, 90, 9251-9262.  | 3.4 | 31        |
| 94  | Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E5328-36.  | 7.1 | 180       |
| 95  | Neuromuscular NMDA Receptors Modulate Developmental Synapse Elimination. <i>Journal of Neuroscience</i> , 2016, 36, 8783-8789.  | 3.6 | 39        |
| 96  | Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 10676-10691.                                     | 6.4 | 58        |
| 97  | Sustained Accumulation of Microtubule-Binding Chemotherapy Drugs in the Peripheral Nervous System: Correlations with Time Course and Neurotoxic Severity. <i>Cancer Research</i> , 2016, 76, 3332-3339.                             | 0.9 | 36        |
| 98  | Oral administration of D-alanine in monkeys robustly increases plasma and cerebrospinal fluid levels but experimental D-amino acid oxidase inhibitors had minimal effect. <i>Journal of Psychopharmacology</i> , 2016, 30, 887-895. | 4.0 | 5         |
| 99  | Maternal inflammation leads to impaired glutamate homeostasis and up-regulation of glutamate carboxypeptidase II in activated microglia in the fetal/newborn rabbit brain. <i>Neurobiology of Disease</i> , 2016, 94, 116-128.      | 4.4 | 59        |
| 100 | Allosteric Glutaminase Inhibitors Based on a 1,4-Di(5-amino-1,3,4-thiadiazol-2-yl)butane Scaffold. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 520-524.   | 2.8 | 50        |
| 101 | Dose-dependent inhibition of GCP II to prevent and treat cognitive impairment in the EAE model of multiple sclerosis. <i>Brain Research</i> , 2016, 1635, 105-112.  | 2.2 | 19        |
| 102 | Effects of Paclitaxel and Eribulin in Mouse Sciatic Nerve: A Microtubule-Based Rationale for the Differential Induction of Chemotherapy-Induced Peripheral Neuropathy. <i>Neurotoxicity Research</i> , 2016, 29, 299-313.           | 2.7 | 27        |
| 103 | d-Amino acid oxidase inhibitors based on the 5-hydroxy-1,2,4-triazin-6(1H)-one scaffold. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2088-2091.   | 2.2 | 12        |
| 104 | Discovery of Orally Available Prodrugs of the Glutamate Carboxypeptidase II (GCP II) Inhibitor 2-Phosphonomethylpentanedioic Acid (2-PMPA). <i>Journal of Medicinal Chemistry</i> , 2016, 59, 2810-2819.                            | 6.4 | 25        |
| 105 | D-Amino-Acid Oxidase Inhibition Increases D-Serine Plasma Levels in Mouse But not in Monkey or Dog. <i>Neuropsychopharmacology</i> , 2016, 41, 1610-1619.   | 5.4 | 19        |
| 106 | FOLH1/GCP II is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities. <i>JCI Insight</i> , 2016, 1, .  | 5.0 | 35        |
| 107 | High-Throughput Assay Development for Cystine-Glutamate Antiporter (xc-) Highlights Faster Cystine Uptake than Glutamate Release in Glioma Cells. <i>PLoS ONE</i> , 2015, 10, e0127785.   | 2.5 | 14        |
| 108 | Selective CNS Uptake of the GCP-II Inhibitor 2-PMPA following Intranasal Administration. <i>PLoS ONE</i> , 2015, 10, e0131861.  | 2.5 | 25        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 109 | Gastrointestinal delivery of propofol from fospropofol: its bioavailability and activity in rodents and human volunteers. <i>Journal of Translational Medicine</i> , 2015, 13, 170.  | 4.4  | 11        |
| 110 | Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron). <i>Cancer Treatment Reviews</i> , 2015, 41, 904-913.                       | 7.7  | 27        |
| 111 | Neurological sequelae induced by alphavirus infection of the CNS are attenuated by treatment with the glutamine antagonist 6-diazo-5-oxo-l-norleucine. <i>Journal of NeuroVirology</i> , 2015, 21, 159-173.                                    | 2.1  | 25        |
| 112 | Bioanalysis of 6-diazo-5-oxo-l-norleucine in plasma and brain by ultra-performance liquid chromatography mass spectrometry. <i>Analytical Biochemistry</i> , 2015, 474, 28-34.   | 2.4  | 14        |
| 113 | Using click chemistry toward novel 1,2,3-triazole-linked dopamine D3 receptor ligands. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 4000-4012.  | 3.0  | 29        |
| 114 | High Affinity Dopamine D <sub>3</sub> Receptor (D <sub>3</sub> R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D <sub>3</sub> R Knockout Mice. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6195-6213. | 6.4  | 45        |
| 115 | Tackling reproducibility in academic preclinical drug discovery. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 733-734.   | 46.4 | 62        |
| 116 | Preventing Allograft Rejection by Targeting Immune Metabolism. <i>Cell Reports</i> , 2015, 13, 760-770.  | 6.4  | 156       |
| 117 | Incorporation of metabolically stable ketones into a small molecule probe to increase potency and water solubility. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4787-4792.   | 2.2  | 93        |
| 118 | 6-Hydroxy-1,2,4-triazine-3,5(2 <i>H</i> ,4 <i>H</i> )-dione Derivatives as Novel <i>d</i> -Amino Acid Oxidase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 7258-7272.   | 6.4  | 29        |
| 119 | Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. <i>Journal of Clinical Investigation</i> , 2015, 125, 2293-2306.   | 8.2  | 319       |
| 120 | Cambinol, a Novel Inhibitor of Neutral Sphingomyelinase 2 Shows Neuroprotective Properties. <i>PLoS ONE</i> , 2015, 10, e0124481.  | 2.5  | 77        |
| 121 | Glutamate Carboxypeptidase II Inhibition Behaviorally and Physiologically Improves Pyridoxine-Induced Neuropathy in Rats. <i>PLoS ONE</i> , 2014, 9, e102936.  | 2.5  | 13        |
| 122 | Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. <i>ELife</i> , 2014, 3, e02523.   | 6.0  | 1,296     |
| 123 | Inhibition of Microglia Activation as a Phenotypic Assay in Early Drug Discovery. <i>Journal of Biomolecular Screening</i> , 2014, 19, 17-31.  | 2.6  | 43        |
| 124 | Regional brain distribution of translocator protein using [11C]DPA-713 PET in individuals infected with HIV. <i>Journal of NeuroVirology</i> , 2014, 20, 219-232.  | 2.1  | 78        |
| 125 | Structure-Metabolism Relationships in the Glucuronidation of <i>d</i> -Amino Acid Oxidase Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 1251-1253.   | 2.8  | 5         |
| 126 | Peptidomimetics of Arg-Phe-NH <sub>2</sub> as small molecule agonists of Mas-related gene C (MrgC) receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 5831-5837.   | 3.0  | 5         |



| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 127 | Î-Thiolactones as Prodrugs of Thiol-Based Glutamate Carboxypeptidase II (GCPII) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 243-247.   | 6.4  | 26        |
| 128 | Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells. <i>Experimental Brain Research</i> , 2014, 232, 2637-2644.   | 1.5  | 35        |
| 129 | Small molecule glutaminase inhibitors block glutamate release from stimulated microglia. <i>Biochemical and Biophysical Research Communications</i> , 2014, 443, 32-36.  | 2.1  | 54        |
| 130 | Bioanalytical method for evaluating the pharmacokinetics of the GCP-II inhibitor 2-phosphonomethyl pentanedioic acid (2-PMPA). <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 88, 162-169.   | 2.8  | 14        |
| 131 | Molecular mechanisms of 5-HT <sub>3</sub> and NK1 receptor antagonists in prevention of emesis. <i>European Journal of Pharmacology</i> , 2014, 722, 26-37.  | 3.5  | 123       |
| 132 | Neuropathy-Inducing Effects of Eribulin Mesylate Versus Paclitaxel in Mice with Preexisting Neuropathy. <i>Neurotoxicity Research</i> , 2013, 24, 338-344.   | 2.7  | 26        |
| 133 | Targeting the Glutamatergic System for the Treatment of HIV-Associated Neurocognitive Disorders. <i>Journal of Neuroimmune Pharmacology</i> , 2013, 8, 594-607.  | 4.1  | 75        |
| 134 | Glutamate Carboxypeptidase II. , 2013, , 1620-1627.  |      | 6         |
| 135 | Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors. <i>Biochemical and Biophysical Research Communications</i> , 2013, 438, 243-248.   | 2.1  | 59        |
| 136 | Bringing together the academic drug discovery community. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 811-812.   | 46.4 | 56        |
| 137 | Synthesis of kojic acid derivatives as secondary binding site probes of d-amino acid oxidase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 3910-3913.   | 2.2  | 20        |
| 138 | Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme. <i>FASEB Journal</i> , 2013, 27, 2620-2625.  | 0.5  | 4         |
| 139 | Pharmacokinetics and Pharmacodynamics of the Glutamate Carboxypeptidase II Inhibitor 2-MPPA Show Prolonged Alleviation of Neuropathic Pain through an Indirect Mechanism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 346, 406-413.       | 2.5  | 22        |
| 140 | Biodistribution, Tumor Detection, and Radiation Dosimetry of <sup>18</sup> F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1883-1891. | 5.0  | 264       |
| 141 | The Orally Active Glutamate Carboxypeptidase II Inhibitor E2072 Exhibits Sustained Nerve Exposure and Attenuates Peripheral Neuropathy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 343, 746-754.   | 2.5  | 17        |
| 142 | Inhibition of Glutamate Carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 20101-20106.                       | 7.1  | 57        |
| 143 | Reversible Disulfide Formation of the Glutamate Carboxypeptidase II Inhibitor E2072 Results in Prolonged Systemic Exposures In Vivo. <i>Drug Metabolism and Disposition</i> , 2012, 40, 2315-2323.   | 3.3  | 7         |
| 144 | Pharmacokinetics of Oral d-Serine in d-Amino Acid Oxidase Knockout Mice. <i>Drug Metabolism and Disposition</i> , 2012, 40, 2067-2073.   | 3.3  | 42        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 145 | Design, Synthesis, and Pharmacological Evaluation of Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl Sulfide 3 (BPTES) Analogs as Glutaminase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10551-10563.          | 6.4  | 163       |
| 146 | Synthesis and Biological Evaluation of Low Molecular Weight Fluorescent Imaging Agents for the Prostate-Specific Membrane Antigen. <i>Bioconjugate Chemistry</i> , 2012, 23, 2377-2385.  | 3.6  | 84        |
| 147 | Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B Cells. <i>Cell Metabolism</i> , 2012, 15, 110-121.  | 16.2 | 923       |
| 148 | Design, Synthesis, and Pharmacological Evaluation of Glutamate Carboxypeptidase II (GCPII) Inhibitors Based on Thioalkylbenzoic Acid Scaffolds. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 5922-5932.                           | 6.4  | 26        |
| 149 | Synthesis and SAR of 1-Hydroxy-1 <i>H</i> -benzo[ <i>d</i> ]imidazol-2(3 <i>H</i> )-ones as Inhibitors of <i>d</i> -Amino Acid Oxidase. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 839-843.                                     | 2.8  | 27        |
| 150 | Pharmacological mechanisms of 5-HT <sub>3</sub> and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. <i>European Journal of Pharmacology</i> , 2012, 684, 1-7.                                  | 3.5  | 112       |
| 151 | Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects. <i>European Journal of Pharmacology</i> , 2012, 689, 25-30.   | 3.5  | 72        |
| 152 | Inhibition of  transporter-mediated cystine uptake by sulfasalazine analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 6184-6187. | 2.2  | 34        |
| 153 | Orally active glutamate carboxypeptidase II inhibitor 2-MPPA attenuates dizocilpine-induced prepulse inhibition deficits in mice. <i>Brain Research</i> , 2011, 1371, 82-86.   | 2.2  | 23        |
| 154 | Comparison of Neuropathy-Inducing Effects of Eribulin Mesylate, Paclitaxel, and Ixabepilone in Mice. <i>Cancer Research</i> , 2011, 71, 3952-3962.   | 0.9  | 85        |
| 155 | Reduced BACE1 Activity Enhances Clearance of Myelin Debris and Regeneration of Axons in the Injured Peripheral Nervous System. <i>Journal of Neuroscience</i> , 2011, 31, 5744-5754.   | 3.6  | 76        |
| 156 | Glutamate Carboxypeptidase Inhibition Reduces the Severity of Chemotherapy-Induced Peripheral Neurotoxicity in Rat. <i>Neurotoxicity Research</i> , 2010, 17, 380-391.   | 2.7  | 59        |
| 157 | Palonosetron triggers 5-HT <sub>3</sub> receptor internalization and causes prolonged inhibition of receptor function. <i>European Journal of Pharmacology</i> , 2010, 626, 193-199.   | 3.5  | 172       |
| 158 | Oral administration of the NAALADase inhibitor GPI-5693 attenuates cocaine-induced reinstatement of drug-seeking behavior in rats. <i>European Journal of Pharmacology</i> , 2010, 627, 156-161.                                       | 3.5  | 24        |
| 159 | Consecutive low doses of cyclophosphamide preferentially target Tregs and potentiate T cell responses induced by DNA PLG microparticle immunization. <i>Cellular Immunology</i> , 2010, 262, 150-161.                                  | 3.0  | 33        |
| 160 | Bioanalysis of N-acetyl-aspartyl-glutamate as a marker of glutamate carboxypeptidase II inhibition. <i>Analytical Biochemistry</i> , 2010, 404, 94-96.   | 2.4  | 6         |
| 161 | The discovery and structure-activity relationships of indole-based inhibitors of glutamate carboxypeptidase II. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 7222-7225.   | 2.2  | 13        |
| 162 | Inhibition of NAALADase by 2-PPMPA attenuates cocaine-induced relapse in rats: a NAAG-GluR2/3-mediated mechanism. <i>Journal of Neurochemistry</i> , 2010, 112, 564-576.   | 3.9  | 51        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 163 | The Antiemetic 5-HT <sub>3</sub> Receptor Antagonist Palonosetron Inhibits Substance P-Mediated Responses In Vitro and In Vivo. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 335, 362-368. | 2.5 | 123       |
| 164 | Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1. <i>Cancer Research</i> , 2010, 70, 8981-8987.  | 0.9 | 439       |
| 165 | <i>In vitro</i> and <i>In vivo</i> Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016. <i>Clinical Cancer Research</i> , 2009, 15, 607-612.                              | 7.0 | 156       |
| 166 | GCP II inhibition rescues neurons from gp120IIIB-induced neurotoxicity. <i>Journal of NeuroVirology</i> , 2009, 15, 449-457.   | 2.1 | 15        |
| 167 | Structural Basis of Interactions between Human Glutamate Carboxypeptidase II and Its Substrate Analogs. <i>Journal of Molecular Biology</i> , 2008, 376, 1438-1450.  | 4.2 | 79        |
| 168 | Structural Insight into the Pharmacophore Pocket of Human Glutamate Carboxypeptidase II. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 3267-3273.  | 6.4 | 71        |
| 169 | Progress in the discovery and development of glutamate carboxypeptidase II inhibitors. <i>Drug Discovery Today</i> , 2007, 12, 767-776.  | 6.4 | 102       |
| 170 | Structural Optimization of Thiol-Based Inhibitors of Glutamate Carboxypeptidase II by Modification of the P1 Side Chain. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 2876-2885.                              | 6.4 | 42        |
| 171 | New Approaches to Chemotherapy-Induced Nausea and Vomiting. <i>Cancer Journal (Sudbury, Mass )</i> , 2006, 12, 341-347.  | 2.0 | 42        |
| 172 | Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. <i>EMBO Journal</i> , 2006, 25, 1375-1384.   | 7.8 | 241       |
| 173 | Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury. <i>Journal of Neurochemistry</i> , 2005, 95, 314-323.   | 3.9 | 62        |
| 174 | Inhibition of glutamate carboxypeptidase II (NAALADase) protects against dynorphin A-induced ischemic spinal cord injury in rats. <i>European Journal of Pharmacology</i> , 2005, 508, 115-122.                    | 3.5 | 21        |
| 175 | DPP IV inhibitor blocks mescaline-induced scratching and amphetamine-induced hyperactivity in mice. <i>Brain Research</i> , 2005, 1048, 177-184.   | 2.2 | 26        |
| 176 | 2-MPPA, a selective glutamate carboxypeptidase II inhibitor, attenuates morphine tolerance but not dependence in C57/Bl mice. <i>Psychopharmacology</i> , 2005, 183, 275-284.                                      | 3.1 | 14        |
| 177 | Enantiospecificity of Glutamate Carboxypeptidase II Inhibition. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 2319-2324.   | 6.4 | 25        |
| 178 | GCP II (NAALADase) Inhibition Suppresses Mossy Fiber-CA3 Synaptic Neurotransmission by a Presynaptic Mechanism. <i>Journal of Neurophysiology</i> , 2004, 91, 182-193.   | 1.8 | 75        |
| 179 | Amino acids at the N- and C-termini of human glutamate carboxypeptidase II are required for enzymatic activity and proper folding. <i>FEBS Journal</i> , 2004, 271, 2782-2790.                                     | 0.2 | 29        |
| 180 | Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. <i>Protein Science</i> , 2004, 13, 1627-1635.   | 7.6 | 93        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 181 | Effects of GCP-II inhibition on responses of dorsal horn neurones after inflammation and neuropathy: an electrophysiological study in the rat. <i>Neuropeptides</i> , 2003, 37, 298-306.  | 2.2 | 49        |
| 182 | Synthesis and biological evaluation of hydroxamate-Based inhibitors of glutamate carboxypeptidase II. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 2097-2100.  | 2.2 | 46        |
| 183 | Effect of middle cerebral artery occlusion on mRNA expression for the sodium-coupled vitamin C transporter SVCT2 in rat brain. <i>Journal of Neurochemistry</i> , 2003, 86, 896-906.  | 3.9 | 63        |
| 184 | Synthesis and Biological Evaluation of Thiol-Based Inhibitors of Glutamate Carboxypeptidase II: Discovery of an Orally Active GCP II Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 1989-1996.                                  | 6.4 | 100       |
| 185 | Mouse brain serine racemase catalyzes specific elimination of L-serine to pyruvate. <i>FEBS Letters</i> , 2003, 535, 44-48.   | 2.8 | 78        |
| 186 | Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 9554-9559.   | 7.1 | 115       |
| 187 | Morphine Tolerance and Reward but not Expression of Morphine Dependence are Inhibited by the Selective Glutamate Carboxypeptidase II (GCP II, NAALADase) Inhibitor, 2-PMPA. <i>Neuropsychopharmacology</i> , 2003, 28, 457-467.               | 5.4 | 41        |
| 188 | Effect of 2-(Phosphono-methyl)-pentanedioic Acid on Allodynia and Afferent Ectopic Discharges in a Rat Model of Neuropathic Pain. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 300, 662-667.                          | 2.5 | 52        |
| 189 | NAALADase (GCP II) inhibition prevents cocaine-kindled seizures. <i>Neuropharmacology</i> , 2002, 43, 348-356.  | 4.1 | 35        |
| 190 | Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. <i>Journal of Neurochemistry</i> , 2002, 80, 477-487.  | 3.9 | 113       |
| 191 | Phosphonate and phosphinate analogues of N-Acylated $\hat{I}^3$ -glutamylglutamate. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 2189-2192.  | 2.2 | 23        |
| 192 | Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay. <i>Analytical Biochemistry</i> , 2002, 310, 50-54.   | 2.4 | 60        |
| 193 | Design and Pharmacological Activity of Phosphinic Acid Based NAALADase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 4170-4175.   | 6.4 | 90        |
| 194 | Expression and acquisition of the conditioned place preference response to cocaine in rats is blocked by selective inhibitors of the enzyme N-acetylated- $\hat{I}$ -linked-acidic dipeptidase (NAALADASE). <i>Synapse</i> , 2001, 41, 22-28. | 1.2 | 55        |
| 195 | Neuroprotection mediated by glutamate carboxypeptidase II (NAALADase) inhibition requires TGF- $\hat{I}^2$ . <i>European Journal of Pharmacology</i> , 2001, 430, 33-40.  | 3.5 | 41        |
| 196 | Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. <i>Prostate</i> , 2000, 45, 350-354.  | 2.3 | 112       |
| 197 | Modulation of behavioral sensitization to cocaine by NAALADase inhibition. <i>Synapse</i> , 2000, 38, 161-166.  | 1.2 | 33        |
| 198 | Neuroprotection produced by the NAALADase inhibitor 2-PMPA in rat cerebellar neurons. <i>European Journal of Pharmacology</i> , 2000, 402, 31-37.   | 3.5 | 41        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 199 | N-acetylated- $\beta$ -linked-acidic dipeptidase inhibitor has a neuroprotective effect on mouse retinal ganglion cells after pressure-induced ischemia. <i>Neuroscience Letters</i> , 2000, 292, 134-136.              | 2.1  | 34        |
| 200 | Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. <i>Nature Medicine</i> , 1999, 5, 1396-1402.  | 30.7 | 281       |
| 201 | Toxicity induced by a polyglutamated folate analog is attenuated by NAALADase inhibition. <i>Brain Research</i> , 1999, 843, 48-52.   | 2.2  | 6         |
| 202 | Characterization of the enzymatic activity of PSM: Comparison with brain NAALADase. , 1999, 39, 28-35.  |      | 82        |
| 203 | Use of identical assay conditions for cocaine analog binding and dopamine uptake to identify potential cocaine antagonists. <i>Drug and Alcohol Dependence</i> , 1997, 48, 43-50.                                       | 3.2  | 33        |
| 204 | Design, Synthesis, and Biological Activity of a Potent Inhibitor of the Neuropeptidase N-Acetylated $\beta$ -Linked Acidic Dipeptidase. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 619-622.                      | 6.4  | 230       |
| 205 | A shot in the arm for cocaine addiction. <i>Nature Medicine</i> , 1996, 2, 26-27.   | 30.7 | 2         |
| 206 | Abnormal acidic amino acids and N-acetylasparylglutamate in hereditary canine motoneuron disease. <i>Brain Research</i> , 1993, 629, 305-309.   | 2.2  | 14        |
| 207 | Immunocytochemical distribution of n-acetylasparylglutamate in the rat forebrain and glutamatergic pathways. <i>Journal of Chemical Neuroanatomy</i> , 1993, 6, 277-292.  | 2.1  | 32        |
| 208 | Genetically epilepsy-prone rats have increased brain regional activity of an enzyme which liberates glutamate from N-acetyl-aspartyl-glutamate. <i>Brain Research</i> , 1992, 593, 140-143.                             | 2.2  | 37        |
| 209 | Immunocytochemical localization of the N-acetyl-aspartyl-glutamate (NAAG) hydrolyzing enzyme N-acetylated $\beta$ -linked acidic dipeptidase (NAALADase). <i>Journal of Comparative Neurology</i> , 1992, 315, 217-229. | 1.6  | 91        |
| 210 | Phosphonates and Phosphonate Prodrugs in Medicinal Chemistry: Past Successes and Future Prospects. <i>Frontiers in Chemistry</i> , 0, 10, .   | 3.6  | 27        |